Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Homoharringtonine Rapidly Clears SARS-CoV-2 in Preclinical M

    2026-05-02

    Homoharringtonine Rapidly Clears SARS-CoV-2 in Preclinical Models

    Study Background and Research Question

    Homoharringtonine is a plant-derived cytotoxic alkaloid long recognized for its efficacy in leukemia research due to its ability to bind the eukaryotic 80S ribosome and inhibit protein synthesis. While its mechanism of inducing G1 phase arrest in leukemic cells is well documented, recent interest has shifted to its potential as an antiviral agent, especially against emerging coronaviruses. The central research question addressed by Wen et al. (2025) is whether homoharringtonine can offer fast, effective viral clearance from the upper respiratory tract during SARS-CoV-2 infection, and if so, whether this could position the compound as a first-line defense in future coronavirus epidemics (paper).

    Key Innovation from the Reference Study

    The pivotal innovation lies in repurposing homoharringtonine—a molecule with a well-characterized cytotoxic mode of action in cancer biology—as a broad-spectrum antiviral. The study demonstrates that homoharringtonine directly blocks protein chain elongation in infected cells, leading to rapid suppression of SARS-CoV-2 replication. Notably, this inhibitory effect was observed at nanomolar concentrations in vitro, highlighting both potency and the mechanistic rationale for targeting viral protein synthesis machinery (paper).

    Methods and Experimental Design Insights

    Wen et al. implemented a multi-tiered experimental pipeline:
    • In vitro assays assessed SARS-CoV-2 replication in cell cultures exposed to varying concentrations of homoharringtonine, establishing a quantitative dose-response relationship.
    • Animal models utilized daily nasal dripping of homoharringtonine (40 μg per dose) in mice post-infection to track viral clearance kinetics in the upper respiratory tract.
    • Early clinical evaluation involved two small cohorts. In the first, 26 cancer patients received 1 mg/day by nebulization. In the second, 11 otherwise healthy patients received 0.2 mg/day by repeated nasal spray during an Omicron wave. Viral loads were monitored longitudinally by PCR.
    This design enabled the authors to bridge molecular mechanism, preclinical efficacy, and real-world applicability across distinct subject groups (paper).

    Protocol Parameters

    • in vitro SARS-CoV-2 inhibition | nanomolar range | virology/cell culture | Demonstrated potent suppression of viral replication at low concentrations | paper
    • animal model nasal administration | 40 μg/day | mouse preclinical | Cleared virus from upper respiratory tract in all treated mice within 3 days | paper
    • human nebulization | 1 mg/day | cancer patient cohort | Reduced URT viral load by ~75% within 6 hours post-dosing | paper
    • human nasal spray | 0.2 mg/day | mild COVID-19, Omicron wave | Cleared virus in 10/11 patients within 2–4 days; typically requires 7–9 days without intervention | paper
    • compound storage | -20°C | all research settings | Maintains stability and activity | product_spec
    • compound solubility | ≥10.92 mg/mL in ethanol, ≥181.2 mg/mL in DMSO | solution preparation | Facilitates formulation for in vitro and in vivo use | product_spec

    Core Findings and Why They Matter

    The study's central finding is the rapid, robust antiviral effect of homoharringtonine against SARS-CoV-2 across three models:
    • In vitro, homoharringtonine completely suppressed replication of SARS-CoV-2 and other coronaviruses at nanomolar concentrations (paper).
    • In mice, daily nasal application cleared the virus from the upper respiratory tract in all animals within three days (paper).
    • In two small clinical cohorts, both nebulized and nasal spray delivery led to rapid viral load reduction—often achieving PCR negativity in 2–4 days compared with 7–9 days in untreated populations (paper).
    No severe adverse effects were reported in either clinical group. These findings support the feasibility of targeting host protein synthesis to achieve rapid viral clearance, positioning homoharringtonine as a mechanistically distinct intervention compared to direct-acting antivirals. The implication for future outbreaks is substantial: a scalable, nasal spray-based protocol could be rapidly deployed at the onset of novel respiratory coronavirus epidemics, potentially curtailing community transmission (paper).

    Comparison with Existing Internal Articles

    Recent internal thought-leadership resources have outlined the dual-domain relevance of homoharringtonine. For example, "Homoharringtonine: Translational Leverage in Oncology and Virology" contextualizes these reference findings, mapping out how the compound's 80S ribosome inhibition underpins both its anti-leukemic and antiviral activities. Similarly, "Homoharringtonine: Cytotoxic Alkaloid Workflows in Cancer & Antiviral Research" translates the latest protocol data into actionable workflow recommendations for researchers aiming to maximize rapid viral inhibition. These internal articles reinforce the cross-domain strategy articulated by Wen et al., connecting the mechanistic rationale to practical assay design and resistance troubleshooting. The present reference study provides critical, peer-reviewed evidence that substantiates these workflow recommendations for both oncology and virology research.

    Limitations and Transferability

    Despite compelling preclinical and pilot clinical data, the study is limited by the small size and non-randomized nature of its human cohorts. The majority of human data derives from special populations (cancer patients, mild Omicron cases) and may not generalize to broader or more severe COVID-19 presentations. Additionally, while no adverse effects were reported in these cohorts, the long-term safety of repeated homoharringtonine administration by nasal or nebulized routes in non-cancer patients remains to be fully established (paper). Transferability to other coronaviruses or respiratory pathogens is promising but requires further validation. The protocol's reliance on early intervention (within days of infection onset) also highlights the importance of rapid diagnosis and deployment for maximal effect.

    Why this cross-domain matters, maturity, and limitations

    The cross-domain repurposing of homoharringtonine from leukemia research to antiviral application is rooted in a shared mechanistic axis—the inhibition of the eukaryotic 80S ribosome and consequent disruption of protein chain elongation. This molecular action is central to both G1 phase arrest in leukemic cells and the blockade of SARS-CoV-2 replication. However, the maturity of evidence is currently highest in oncology, with antiviral applications still in translational and early clinical phases. As such, while the mechanistic bridge is clear and experimentally validated, larger randomized trials are needed to solidify clinical recommendations (paper; internal_article).

    Research Support Resources

    Researchers interested in recapitulating or extending these workflows can access homoharringtonine (SKU N1504) from APExBIO (product page). This reagent is supplied with detailed solubility and storage guidelines to ensure experimental reproducibility in both cancer biology and SARS-CoV-2 antiviral research contexts. For further mechanistic and protocol guidance, the above-cited internal resources offer practical advice for integrating homoharringtonine into translational research pipelines.